Navigation Links
Essentialis to Submit SPA for Hypertriglyceridemia
Date:8/11/2009

CARLSBAD, Calif., Aug. 11 /PRNewswire/ -- Essentialis, Inc., a clinical stage pharmaceutical company, announced today its intention to file a Special Protocol Assessment (SPA) with the FDA for the pivotal study to support the NDA filing on its lead drug, DCCR, for the treatment of very high triglycerides. The proposed study would include 280 randomized subjects with the primary efficacy endpoint assessed at 12 weeks. This decision followed a productive Type C meeting with the FDA on July 30th, where the overall development plan for DCCR and the non-clinical package supporting the NDA were reviewed and discussed. Commenting on this development, Essentialis President and CEO Iain Dukes stated, "The submission of the SPA will bring us one step closer towards filing for approval of DCCR for the treatment of patients with very high triglycerides. This development, along with positive Phase 2 study results and the recent issuance of a US patent providing extensive protection to DCCR, underscores the tremendous clinical and commercial potential of this drug worldwide."

About DCCR

DCCR, diazoxide choline controlled release tablet, is an ATP-sensitive potassium channel agonist which has potential therapeutic utility in several cardiovascular and metabolic diseases. Extensive Phase 1 testing has demonstrated the drug's potential to lower triglycerides (TG), non-HDL cholesterol and LDL-cholesterol (LDL-C) while raising HDL-cholesterol. In addition, weight loss has been demonstrated in 2 investigator sponsored studies. A Phase 2, 8-week, placebo-controlled, double-blind study involving 90 patients, which was powered to be pivotal, demonstrated statistically significant reductions in triglycerides, without impacting LDL-C. In subjects with elevated LDL-C at baseline, DCCR reduced LDL-C levels. DCCR was generally well tolerated, and most AEs were mild to moderate, resolving without sequelae. US patent 7,57
'/>"/>

SOURCE Essentialis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
2. Essentialis Completes Patient Enrollment in Phase 2 Trial of DDCR for Treatment of Dyslipidemia
3. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
4. Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder
5. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 21, 2014 MEDITE Group acquired by ... months and the 3 rd quarter sales ended September ... was $448,000 for the nine months ended September 2014 and ... though our 3 rd quarter is usually a seasonable ... from July into September for many countries worldwide, we are ...
(Date:11/21/2014)... COLLEGE PARK, Md. , Nov. 21, 2014 /PRNewswire-USNewswire/ ... Engineering today will host the ceremonial groundbreaking of the ... Maryland, College Park. The new building will cultivate transformative ... human health.  Taking place at 10:00 a.m. ... building in the Paint Branch Parking Lot, adjacent to ...
(Date:11/21/2014)... MARCOS, Texas , Nov. 21, 2014  World ... hemp containing low THC, announces they are now offering ... comparable to Charlotte,s Web type strains grown in medical ... from other neurological disorders, such as Parkinson,s, MS, and ... for US laws to pass, because imported CBD Oil ...
Breaking Medicine Technology:CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 2CytoCore Inc. / MEDITE Cancer Diagnostics, Inc. Reports Record YTD and 3rd Quarter Sales 3University of Maryland Breaks Ground for A. James Clark Hall 2University of Maryland Breaks Ground for A. James Clark Hall 3University of Maryland Breaks Ground for A. James Clark Hall 4New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 2New CBD Oil From Industrial Hemp is Comparable to Charlotte's Web, Legal In All 50 States 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... announced that Mr. Ofir Paz, InspireMD,s co-founder and chief ... will participate in the Benchmark Company, LLC One-on-One Investor ... Hotel, 424 East Wisconsin Ave., Milwaukee, Wis. The conference ...
... Axcan Intermediate Holdings Inc. announces that it ... the recently completed combination of two specialty pharma companies ... also has a new corporate logo and website (please ... "Our new name, Aptalis, is intended to capture the ...
Cached Medicine Technology:InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 2InspireMD to Participate in Benchmark Company, LLC 2011 One-On-One Investor Conference 3The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 2The Newly Combined Axcan and Eurand Announce Name Change to Aptalis 3
(Date:11/22/2014)... Nocturia is defined by the ... the individual has to wake at night one ... – Pipeline Review, H2 2014” provides comprehensive information ... comparative analysis at various stages, therapeutics assessment by ... administration (RoA) and molecule type, along with latest ...
(Date:11/22/2014)... 22, 2014 The topic of B&D ... block retaining walls. The article states that, “While they give ... necessary steps that go into creating this powerful look.” , ... retaining wall is choosing which kind of block matches your ... B&D Rockeries says, “The two main options are concrete and ...
(Date:11/22/2014)... FL (PRWEB) November 22, 2014 ... Innovations are pleased to announce that Ashley Lombardo ... Thanksgiving #PayItForward contest. , Ms. Lombardo entered friend ... Kitchen Innovations. She wrote of how her friend is ... daughters as a single mom. Despite medical bills piling ...
(Date:11/22/2014)... “Greenfield Naturals” was featured on NewsWatch as ... features the latest and coolest technology products available to ... NewsWatch, conducted the product review and shared with viewers ... water. , From pollution to hazardous substances in water, ... done to remove these chemicals, especially in water. , ...
(Date:11/22/2014)... FRIDAY, Nov. 21, 2014 (HealthDay News) -- Those air-blown ... germs than conventional paper towels, a new study suggests. ... on the hands of volunteers in order to simulate ... dryers, high-powered "jet-air" dryers or paper towels to dry ... and found higher amounts of germs around both types ...
Breaking Medicine News(10 mins):Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2Health News:Forbes Living TV Announces Winner of Thanksgiving #PayItForward Contest 2Health News:An Easy Home Solution to Get Better Tasting Water was Featured on NewsWatch Television on October 30, 2014 2Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2
... WEDNESDAY, Aug. 25 (HealthDay News) -- Even prior to ... in four American parents with health insurance reported that their ... medical care their children needed. Parents of kids with ... to say their insurance coverage did not meet their needs, ...
... and promise of using thermal ablation to target and ... of Vascular and Interventional Radiology ,s August supplement, "Thermal ... Goals and Future Technology." "The Journal ... on the development of multiple medical techniques and devices ...
... 11 states will receive more than $6 million in ... on substance abuse and associated problems among U.S. military ... Drug Abuse (NIDA), part of the National Institutes of ... to award grants that will examine substance abuse related ...
... treat metastatic melanoma tumors with a specific genetic signature was successful ... clinical trial. Results of the trial of PLX4032, an inhibitor ... half of all melanomas, appear in the August 26 New ... and is one of the top causes of cancer death in ...
... 25 Vitamin D may be an effective therapy to ... can cause severe complications for patients with cystic fibrosis and ... UPMC, the University of Pittsburgh School of Medicine and Louisiana ... by Jay Kolls, M.D., Ph.D., a lung disease researcher at ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
Cached Medicine News:Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Journal of Vascular and Interventional Radiology sees growth, promise of tumor ablation 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 2Health News:Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene 3Health News:Vitamin D may treat and prevent allergic reaction to mold in cystic fibrosis patients 2Health News:Study Links Gene to Serious Eye Disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: